

# **Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/ICEEFE0FF3DAEN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: ICEEFE0FF3DAEN

## **Abstracts**

The 7 major ichthyosiform erythroderma/congenital ichthyosiform erythroderma markets are expected to exhibit a CAGR of 4.35% during 2024-2034.

The ichthyosiform erythroderma/congenital ichthyosiform erythroderma market has been comprehensively analyzed in IMARC's new report titled "Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ichthyosiform erythroderma/congenital ichthyosiform erythroderma (CIE) is a rare genetic skin disorder characterized by abnormal scaling and redness of the skin. It falls under the broader category of ichthyosis, a group of disorders that affect the skin's ability to shed dead cells properly, resulting in dry, thickened, and scaly skin. The symptoms of this illness include widespread and persistent redness of the skin (erythroderma) accompanied by intense scaling, resembling fish-like scales. The skin's impaired barrier function can also lead to increased vulnerability to infections and temperature regulation difficulties. The condition typically presents at birth or shortly thereafter, affecting patients from infancy through adulthood. The diagnosis of the ailment commonly involves a combination of clinical examination, family history assessment, and skin biopsy. Genetic testing is also essential for confirming the diagnosis and identifying the specific underlying genetic mutation responsible for the disorder. Early diagnosis is crucial for appropriate management and treatment.

The escalating prevalence of genetic anomalies affecting various genes, particularly those related to keratinocyte differentiation and skin barrier function, is primarily driving

the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market. In addition to this, the inflating utilization of treatment modalities, such as emollients, topical retinoids, and systemic retinoids for managing symptoms and improving skin texture is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive measures like phototherapy and the avoidance of triggers, including extreme temperatures and harsh soaps, is further bolstering the market growth. Apart from this, the rising usage of physical therapies aimed at maintaining joint flexibility and preventing muscle contractures in individuals suffering from the illness is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative approaches like gene editing and gene replacement therapy, that hold immense potential for rectifying the genetic irregularities responsible for the underlying condition, is also augmenting the market growth. Furthermore, the increasing demand for genetic counseling and prenatal screening, which offer prospective parents vital information on the risks associated with passing the mutated genes to their offspring, thereby boosting a proactive healthcare environment, is expected to drive the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ichthyosiform erythroderma/congenital ichthyosiform erythroderma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

## Countries Covered

United States  
Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

## Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current ichthyosiform erythroderma/congenital ichthyosiform erythroderma marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status

## Clinical Trial Results

### Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

### Market Insights

How has the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of ichthyosiform erythroderma/congenital ichthyosiform erythroderma across the seven major markets?

What is the number of prevalent cases (2018-2034) of ichthyosiform erythroderma/congenital ichthyosiform erythroderma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of ichthyosiform erythroderma/congenital ichthyosiform erythroderma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with ichthyosiform erythroderma/congenital ichthyosiform erythroderma across the seven major markets?

What is the size of the ichthyosiform erythroderma/congenital ichthyosiform erythroderma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of ichthyosiform erythroderma/congenital ichthyosiform erythroderma?

What will be the growth rate of patients across the seven major markets?

Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for ichthyosiform erythroderma/congenital ichthyosiform erythroderma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market?

What are the key regulatory events related to the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market?

What is the structure of clinical trial landscape by status related to the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market?

What is the structure of clinical trial landscape by phase related to the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market?

What is the structure of clinical trial landscape by route of administration related to the ichthyosiform erythroderma/congenital ichthyosiform erythroderma market?

## Contents

?1 Preface

## 2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

## 3 EXECUTIVE SUMMARY

## 4 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - INTRODUCTION

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

## 5 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - DISEASE OVERVIEW

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

## 6 PATIENT JOURNEY

## 7 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM

*Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma Market: Epidemiology, Industry Trends, Share,...*

## **ERYTHRODERMA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy



- 7.7.1 Epidemiology Scenario (2018-2023)
- 7.7.2 Epidemiology Forecast (2024-2034)
- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - UNMET NEEDS**

## **10 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - KEY ENDPOINTS OF TREATMENT**

## **11 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - MARKETING PRODUCTS**

- 11.1 List of Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma Marketed Drugs Across the Top 7 Markets



#### 11.1.1 Drug Name – Company Name

##### 11.1.1.1 Drug Overview

##### 11.1.1.2 Mechanism of Action

##### 11.1.1.3 Regulatory Status

##### 11.1.1.4 Clinical Trial Results

##### 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - PIPELINE DRUGS**

### 12.1 List of Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 TMB 001 - Timber Pharmaceuticals

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 PAT 001 - Timber Pharmaceuticals

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

#### 12.1.3 KB105 - Krystal Biotech

##### 12.1.3.1 Drug Overview

##### 12.1.3.2 Mechanism of Action

##### 12.1.3.3 Clinical Trial Results

##### 12.1.3.4 Safety and Efficacy

##### 12.1.3.5 Regulatory Status

#### 12.1.4 SXR 1096 - Sixera Pharma

##### 12.1.4.1 Drug Overview

##### 12.1.4.2 Mechanism of Action

##### 12.1.4.3 Clinical Trial Results

##### 12.1.4.4 Safety and Efficacy

##### 12.1.4.5 Regulatory Status

#### 12.1.5 QRX 003 - Quoin Pharmaceuticals

##### 12.1.5.1 Drug Overview

12.1.5.2 Mechanism of Action

12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

### **13. ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA – CLINICAL TRIAL LANDSCAPE**

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

### **15 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - MARKET SCENARIO**

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies

- 15.3.2.1 Market Size by Therapies (2018-2023)
- 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market

## Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma - Access and Reimbursement Overview

## **16 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 ICHTHYOSIFORM ERYTHRODERMA/CONGENITAL ICHTHYOSIFORM ERYTHRODERMA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Ichthyosiform Erythroderma/Congenital Ichthyosiform Erythroderma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/ICEEFE0FF3DAEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ICEEFE0FF3DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970